EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Sepideh Mokhtari, Justin M Asquith, Syeda Saba Kareem iD, Christina A Bachmeier, Yolanda Pina, Rawan G Faramand iD, Youngchul Kim, Edwin N Peguero, Solmaz Sahebjam, Mohammad H Jaffer, David P Iacono, Michael D Jain und 5 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26083904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sepideh Mokhtari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Neurotoxicity Syndromes, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe immune effector cell-associated neurotoxicity syndrome (ICANS) occurs in about 30% of all patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel). There are currently limited treatment strategies other than the standard corticosteroids, and it is essential to find additional therapies to manage severe ICANS. We conducted a retrospective study of neurologic outcomes among patients who received axi-cel for LBCL from May 2015 to February 2019. We identified patients who developed severe ICANS and were treated with glucocorticoids followed by intravenous immunoglobulin (IVIG) (n = 9) or glucocorticoids alone (n = 10). There was no statistically significant difference in the time to resolution (TTR) of severe ICANS between groups; however, patients in the IVIG had more severe grades of ICANS with a lower performance status at baseline. The cumulative steroid days were 11.2 in the IVIG arm and 13.5 in the glucocorticoids-only arm. The use of IVIG for severe ICANS after axi-cel therapy was tolerable and safe and is generally recommended in the CAR-T setting in patients with hypogammaglobinemia. The use of IVIG as a potential therapeutic agent for severe ICANS can be further explored in future prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousNeurotoxicity SyndromesImmunotherapy, AdoptiveReceptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultGlucocorticoidsTreatment OutcomeBiological Products

Stichwörter der Autor:innen

CAR-TCAR-T-related encephalopathy syndromeCRESICANSIVIGaxicabtagene ciloleucelneurotoxicity

Substanzen

Immunoglobulins, IntravenousReceptors, Chimeric Antigenaxicabtagene ciloleucelGlucocorticoidsBiological Products

Autor:innen und Institutionen

  • Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
  • Department of Medical Oncology, Aspirus Cancer Care, Wausau, WI 54401, USA.
  • Department of Bone Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 33612, USA.
  • Department of Biostatistics, Moffitt Cancer Center, Tampa, FL 33612, USA.
  • Department of Medical Oncology, John Hopkins Hospital, Washington, DC 20016, USA.
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.

ORCID-Profile: Syeda Saba Kareem, Rawan G Faramand, Marco L Davila, Peter A Forsyth

Zitieren

APA

Mokhtari, S., Asquith, J. M., Kareem, S. S., Bachmeier, C. A., Pina, Y., Faramand, R. G., Kim, Y., Peguero, E. N., Sahebjam, S., Jaffer, M. H., Iacono, D. P., Jain, M. D., Vogelbaum, M. A., Davila, M. L., Forsyth, P. A., Locke, F. L., & Lazaryan, A. (2025). Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083904

Vancouver

Mokhtari S, Asquith JM, Kareem SS, Bachmeier CA, Pina Y, Faramand RG, et al. Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083904

BibTeX
@article{Mokhtari2025,
  author = {Mokhtari, Sepideh and Asquith, Justin M and Kareem, Syeda Saba and Bachmeier, Christina A and Pina, Yolanda and Faramand, Rawan G and Kim, Youngchul and Peguero, Edwin N and Sahebjam, Solmaz and Jaffer, Mohammad H and Iacono, David P and Jain, Michael D and Vogelbaum, Michael A and Davila, Marco L and Forsyth, Peter A and Locke, Frederick L and Lazaryan, Aleksandr},
  title = {Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26083904}
}
Kostenlos starten →